Amerise Biosciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Net Income	0.38	0.06	-1.46	-1.19	5.49	-3.37	Upgrade
Other Operating Activities	-	-	-0	-	-	-	Upgrade
Change in Accounts Receivable	-	-	-	62.17	-62.17	-	Upgrade
Change in Accounts Payable	-	-	-	-62.66	57.85	-	Upgrade
Change in Other Net Operating Assets	30.22	30.65	-0.23	0.36	-0.56	-0.57	Upgrade
Operating Cash Flow	30.6	30.71	-1.69	-1.32	0.61	-3.94	Upgrade
Investment in Securities	-15.05	-1.16	23.01	1.26	-16.51	23.3	Upgrade
Investing Cash Flow	-30.52	-30.7	2.67	1.26	-1.51	3.89	Upgrade
Short-Term Debt Issued	-	-	-	0.07	0.83	-	Upgrade
Total Debt Issued	-	-	-	0.07	0.83	-	Upgrade
Short-Term Debt Repaid	-	-	-0.9	-	-	-	Upgrade
Total Debt Repaid	-	-	-0.9	-	-	-	Upgrade
Net Debt Issued (Repaid)	-	-	-0.9	0.07	0.83	-	Upgrade
Financing Cash Flow	-	-	-0.9	0.07	0.83	-	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	-	-0	0	-	Upgrade
Net Cash Flow	0.08	0.01	0.08	0.01	-0.06	-0.06	Upgrade
Cash Income Tax Paid	0.02	0.02	-	-	-	-	Upgrade
Levered Free Cash Flow	30.47	30.7	-1.14	-1.17	-1.44	-2.68	Upgrade
Unlevered Free Cash Flow	30.47	30.7	-1.14	-1.17	-1.44	-2.68	Upgrade
Change in Working Capital	30.22	30.65	-0.23	-0.13	-4.88	-0.57	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.